{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:31:03Z","timestamp":1785717063369,"version":"3.56.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2020,11,22]],"date-time":"2020-11-22T00:00:00Z","timestamp":1606003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100018817","name":"LUPUS UK","doi-asserted-by":"publisher","award":["1543411"],"award-info":[{"award-number":["1543411"]}],"id":[{"id":"10.13039\/501100018817","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Chronic glucocorticoid use is complicated by osteoporosis and increases the risk of fragility fractures. EULAR guidelines on SLE management recommend reducing chronic glucocorticoid dosage to \u22647.5\u2009mg\/day to minimize this risk. We examined the relationship of glucocorticoid dose to fragility fracture risk in a cohort of SLE patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Retrospective analysis of SLE patients attending University College Hospital over 28\u2009years was undertaken. Collected data included consecutive steroid dose, dual-energy X-ray absorptiometry scans and fragility fractures.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We collected data on 250 patients with a median of 17 years\u2019 follow-up. Fragility fractures were diagnosed in 28 (11.2%) patients and the mean \u00b1 s.d. age of first fracture was 51\u2009\u00b1\u200916\u2009years. A total of 94% received glucocorticoids, the average dose being 6.20\u2009mg\/day. Patients with fragility fractures had a lower average daily dose (5.36 vs 6.23\u2009mg\/day) but a higher median cumulative dose (25.19 vs 20.96\u2009g). These differences were not significant (P = 0.127 and 0.229, respectively). Some 93% of patients received vitamin D, and 85% received calcium. Cox regression analysis showed older age at SLE diagnosis, osteoporosis and secondary hyperparathyroidism were associated with fragility fractures. Glucocorticoid dose was not significantly associated with the occurrence of fragility fractures. Twenty-two patients with fractures were treated with bisphosphonates, two with denosumab and two with teriparatide.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>We found no significant association between glucocorticoid treatment and fragility fractures in our group of patients; however, a prospective study including more patients not treated with CS would be necessary to confirm these results.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa705","type":"journal-article","created":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T12:03:35Z","timestamp":1602677015000},"page":"2765-2772","source":"Crossref","is-referenced-by-count":15,"title":["Fracture risk in systemic lupus erythematosus patients over 28 years"],"prefix":"10.1093","volume":"60","author":[{"given":"Daniela","family":"Garelick","sequence":"first","affiliation":[{"name":"Rheumatology Department, Sheba Medical Center, Ramat Gan, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Moreira","family":"Pinto","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Pedro Hispano Hospital, Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1517-4383","authenticated-orcid":false,"given":"Filipa","family":"Farinha","sequence":"additional","affiliation":[{"name":"Rheumatology Department, University College London Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Pires","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Medicina 1, Hospital de Santo Andr\u00e9, Centro Hospitalar de Leiria, Leiria, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emon","family":"Khan","sequence":"additional","affiliation":[{"name":"Rheumatology Department, University College London Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9514-2455","authenticated-orcid":false,"given":"David","family":"Isenberg","sequence":"additional","affiliation":[{"name":"Rheumatology Department, University College London Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,11,22]]},"reference":[{"key":"2021061821282260600_keaa705-B1","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/rheumatology\/39.12.1383","article-title":"Oral corticosteroids and fracture risk: relationship to daily and cumulative doses","volume":"39","author":"van Staa","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"2021061821282260600_keaa705-B2","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s00198-019-04906-x","article-title":"Glucocorticoid-induced osteoporosis: 2019 concise clinical review","volume":"30","author":"Adami","year":"2019","journal-title":"Osteoporos Int"},{"key":"2021061821282260600_keaa705-B3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s12020-018-1588-2","article-title":"Glucocorticoid-induced osteoporosis: an update","volume":"61","author":"Compston","year":"2018","journal-title":"Endocrine"},{"key":"2021061821282260600_keaa705-B4","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1210\/er.2018-00097","article-title":"Glucocorticoids and bone: consequences of endogenous and exogenous excess and replacement therapy","volume":"39","author":"Hardy","year":"2018","journal-title":"Endocr Rev"},{"key":"2021061821282260600_keaa705-B5","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2021061821282260600_keaa705-B6","doi-asserted-by":"crossref","first-page":"e000066","DOI":"10.1136\/lupus-2014-000066","article-title":"Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus-the Hopkins Lupus Cohort","volume":"2","author":"Al Sawah","year":"2015","journal-title":"Lupus Sci Med"},{"key":"2021061821282260600_keaa705-B7","first-page":"486","article-title":"Osteoporosis in patients with systemic lupus erythematosus","volume":"11","author":"Garc\u00eda-Carrasco","year":"2009","journal-title":"Isr Med Assoc J"},{"key":"2021061821282260600_keaa705-B8","first-page":"1","article-title":"Prevalence and possible risk factors of low bone mineral density in untreated female patients with systemic lupus erythematosus","volume":"2015","author":"Sun","year":"2015","journal-title":"Biomed Res Int"},{"key":"2021061821282260600_keaa705-B9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10067-008-0984-z","article-title":"Risks factors for low bone mineral density in pre-menopausal Mexican women with systemic lupus erythematosus","volume":"28","author":"Mendoza-Pinto","year":"2009","journal-title":"Clin Rheumatol"},{"key":"2021061821282260600_keaa705-B10","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1177\/0961203319855122","article-title":"Ten-year fracture risk by FRAX and osteoporotic fractures in patients with systemic autoimmune diseases","volume":"28","author":"Lai","year":"2019","journal-title":"Lupus"},{"key":"2021061821282260600_keaa705-B11","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1007\/s00198-013-2587-z","article-title":"Elevated risk of clinical fractures and associated risk factors in patients with systemic lupus erythematosus versus matched controls: a population-based study in the United Kingdom","volume":"25","author":"Bultink","year":"2014","journal-title":"Osteoporos Int"},{"key":"2021061821282260600_keaa705-B12","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/art.40818","article-title":"Comparative fracture risks among United States Medicaid enrollees with and those without systemic lupus erythematosus","volume":"71","author":"Tedeschi","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2021061821282260600_keaa705-B13","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/1529-0131(199905)42:5<882::AID-ANR6>3.0.CO;2-C","article-title":"Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data","volume":"42","author":"Ramsey-Goldman","year":"1999","journal-title":"Arthritis Rheum"},{"key":"2021061821282260600_keaa705-B14","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/ard.2006.058313","article-title":"Clinical relevance of vertebral fractures","volume":"66","author":"Lems","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"2021061821282260600_keaa705-B15","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.autrev.2017.09.011","article-title":"Bone mineral density and vitamin D status in systemic lupus erythematosus (SLE): a systematic review","volume":"16","author":"Salman-Monte","year":"2017","journal-title":"Autoimmun Rev"},{"key":"2021061821282260600_keaa705-B16","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s001980200108","article-title":"The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis","volume":"13","author":"Staa","year":"2002","journal-title":"Osteoporos Int"},{"key":"2021061821282260600_keaa705-B17","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1002\/art.11283","article-title":"Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy","volume":"48","author":"Van Staa","year":"2003","journal-title":"Arthritis Rheum"},{"key":"2021061821282260600_keaa705-B18","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1007\/s00198-015-3455-9","article-title":"Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials","volume":"27","author":"Amiche","year":"2016","journal-title":"Osteoporos Int"},{"key":"2021061821282260600_keaa705-B19","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1007\/s00198-016-3646-z","article-title":"Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis","volume":"27","author":"Balasubramanian","year":"2016","journal-title":"Osteoporos Int"},{"key":"2021061821282260600_keaa705-B20","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11657-018-0424-x","article-title":"Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study","volume":"13","author":"Amiche","year":"2018","journal-title":"Arch Osteoporos"},{"key":"2021061821282260600_keaa705-B21","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/acr.20295","article-title":"American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"62","author":"Grossman","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2021061821282260600_keaa705-B22","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1136\/ard.45.11.950","article-title":"Osteoporosis in rheumatoid arthritis: safety of low dose corticosteroids","volume":"45","author":"Sambrook","year":"1986","journal-title":"Ann Rheum Dis"},{"key":"2021061821282260600_keaa705-B23","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1136\/ard.48.7.535","article-title":"Effects of low dose corticosteroids on bone mass in rheumatoid arthritis: a longitudinal study","volume":"48","author":"Sambrook","year":"1989","journal-title":"Ann Rheum Dis"},{"key":"2021061821282260600_keaa705-B24","first-page":"CD000952","article-title":"Calcium and vitamin D for corticosteroid-induced osteoporosis","volume":"1998","author":"Homik","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"2021061821282260600_keaa705-B25","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1177\/0961203318785245","article-title":"Medical adherence in patients with systemic lupus erythematosus in Germany: predictors and reasons for non-adherence\u2014a cross-sectional analysis of the LuLa-cohort","volume":"27","author":"Chehab","year":"2018","journal-title":"Lupus"},{"key":"2021061821282260600_keaa705-B26","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1002\/acr.23191","article-title":"Medication nonadherence in systemic lupus erythematosus: a systematic review","volume":"69","author":"Mehat","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2021061821282260600_keaa705-B27","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1002\/art.40571","article-title":"Comparison of remission and lupus low disease activity state in damage prevention in a united states systemic lupus erythematosus cohort","volume":"70","author":"Petri","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2021061821282260600_keaa705-B28","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.3899\/jrheum.131190","article-title":"Bone mineral density change in systemic lupus erythematosus: a 5-year followup study","volume":"41","author":"Zhu","year":"2014","journal-title":"J Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/6\/2765\/38695191\/keaa705.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/6\/2765\/38695191\/keaa705.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T21:28:50Z","timestamp":1624051730000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/6\/2765\/5998384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,22]]},"references-count":28,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,11,22]]},"published-print":{"date-parts":[[2021,6,18]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa705","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,6,1]]},"published":{"date-parts":[[2020,11,22]]}}}